Pricing Log in Create free account
Friday 6 November 2026 Export INMD’s income statement to Excel — free account

InMode Ltd.

INMD Healthcare Medical Devices

InMode Ltd.’s revenue for fiscal 2025 (year ended December 2025) was $370.5 million, down 6.16% from fiscal 2024.

Revenue
−0.01%
EPS
−31.0%
Free cash flow
−12.6%

Quarter to June 2026, against a year earlier

13.36 0.04 −0.30%
Market cap
$771.1M
P/E
10.7×
Fwd P/E
11.8×
Dividend yield
—
F-score
4/9
Altman Z
10.45
Beneish M
−2.25
Dividend safety
n/a
Overview
Financials
Income Statement Balance Sheet Cash Flow Metrics & Ratios

Insider Decisions last twelve months

Trades a month
Jan 26 Apr 26 Jul 26 Oct 26
Buy — — — — — — — — — — — —
Sell — — — — — — — — — — — —
Insider Ownership 18.31%

Capital & Financial Ratios $m

Size
Market Cap 771.09
Revenue ttm 374.63
Net income ttm 77.51
Free cash flow ttm 82.53
Net debt Q (501.11)
Valuation
P/E 10.70
Forward P/E 11.80
Price / sales 2.10
Forward P/S Powerpack
Price / FCF 9.54
Price / book 1.15
Financial health
Current ratio Q 8.18 (at or above 1.5: strong)
Debt / equity Q 0.00 (at or below 0.5: strong)
Interest coverage Q 9.37
Growth
Revenue growth Q −0.01% (below 0%: shrinking)
Operating income growth Q −46.43% (below 0%: shrinking)
EPS, this year −19.01% (below 0%: weak)
EPS, next year A +5.84%
Revenue, next year A −0.05% (below 0%: weak)
EPS, past 5 yrs +9.95%
EPS, next 5 yrs A −3.28% (below 0%: weak)

Green and red mark values outside typical ranges; (Q) is the latest quarter, (A) analysts’ estimates. How we judge →

Valuation vs history

EV/Sales, ten years
EV/Sales is 0.8×, against a ten-year median of 4.2×; over the ten years it ranged from 0.7× in 2026 to 23.1× in 2021.
P/E against its own 10 years 37.43%
10-year low 10-year high
P/S against its own 10 years 0.16%
10-year low 10-year high
P/B against its own 10 years 0.16%
10-year low 10-year high
EV/Sales against its own 10 years 0.22%
10-year low 10-year high
EV/FCF against its own 10 years 0.99%
10-year low 10-year high

Dividends

Yield
—
Annual rate
—
Payout ratio
—

Assets vs Liabilities $m

2023 2024 2025 Q'26
Cash 742 596 555 501
Receivables 59 58 69 77
Inventory 45 60 74 72
Other — — — —
845 714 699 650
2023 2024 2025 Q'26
Payables 14 14 18 19
ST’ Debt — — — —
Other 50 56 53 61
64 70 71 79

Compound Annual Growth %

10y 5y 3y
Sales — 12.44% (6.57%)
Cash Flow — 1.48% (22.28%)
Earnings — 4.57% (16.56%)
Book Value — 21.74% 7.20%

Earnings Trends EPS, adjusted, against the consensus

Jun 2025 Estimate 0.43 Actual 0.47

Earnings per share against the consensus, by quarter
Quarter Estimate Reported Result
Sep 2024 0.57 0.70 Beat by 0.13
Dec 2024 0.50 0.42 Miss by 0.08
Mar 2025 0.33 0.31 Miss by 0.02
Jun 2025 0.43 0.47 Beat by 0.04

EPS $

Mar Jun Sep Dec Year
’26 0.18 0.29 — — —
’25 0.26 0.42 0.34 0.42 1.43
’24 0.28 0.28 0.65 1.14 2.25
’23 0.47 0.65 0.54 0.64 2.30
’22 0.36 0.52 0.58 0.44 1.89
’21 0.32 0.48 0.52 0.61 1.92
’20 0.08 0.11 0.29 0.43 0.89
Fiscal quarters ending in the months shown.

Revenue $m

Mar Jun Sep Dec Year
’26 82 96 — — —
’25 78 96 93 104 370
’24 80 86 130 98 395
’23 106 136 123 127 492
’22 86 114 121 134 454
’21 66 87 94 111 358
’20 40 31 60 75 206
Fiscal quarters ending in the months shown.

Operating Cash Flow $m

Mar Jun Sep Dec Year
’26 15 21 — — —
’25 14 24 24 23 85
’24 24 42 34 32 133
’23 21 53 41 61 177
’22 32 47 46 57 182
’21 25 47 50 53 175
’20 6 1 30 42 79
Fiscal quarters ending in the months shown.

Free Cash Flow $m

Mar Jun Sep Dec Year
’26 15 21 — — —
’25 14 24 24 22 84
’24 24 42 34 32 132
’23 21 53 41 61 176
’22 32 46 45 57 180
’21 25 46 50 53 174
’20 6 1 30 42 79
Fiscal quarters ending in the months shown.

Target Price Range

Analyst price targets

Recommendation Rating

3
1Buy 2 3Hold 4 5Sell

Ten years at a glance Fiscal years to December

Ten-year view Analyst estimates Powerpack
Group Line 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 TTM Jun ’26 Trend 10 yrs 2026e 2027e 2028e Next 3/yr
Income, $m
Income, $m Revenue — 53 100 156 206 358 454 492 395 370 375 +27.4% 370 379 389 +1.6%
Gross margin, % — 83.06 84.97 87.06 85.03 85.01 83.82 83.60 80.31 78.54 76.52 (4.5) pt
EBT — 10 24 62 76 168 201 217 143 110 91 +35.3%
EBT margin, % — 18.33 23.59 39.68 36.94 46.99 44.35 44.16 36.34 29.78 24.28 +11.5 pt
Net income — 9 22 61 75 165 162 198 181 94 78 +34.4%
Per share, $
Per share, $ Revenue — 1.02 1.88 2.67 2.86 4.39 5.51 5.89 4.98 5.73 6.36 +24.1%
Earnings — 0.17 0.42 1.05 1.04 2.03 1.96 2.37 2.29 1.45 1.25 +30.9%
Cash flow — 0.28 0.69 1.06 1.10 2.15 2.20 2.12 1.67 1.32 1.42 +21.5%
Capex — 0.00 (0.01) (0.01) (0.01) (0.01) (0.02) (0.01) (0.01) (0.01) (0.02) +19.5%
Free cash flow — 0.27 0.69 1.05 1.09 2.14 2.18 2.11 1.66 1.30 1.40 +21.5%
Book value — 0.37 0.84 3.08 3.54 5.11 6.72 9.43 8.87 10.57 10.68 +52.0%
Shares, m — 53 53 58 72 81 82 84 79 65 63 +2.6%
Valuation, ×
Valuation, × P/E — 10.66 10.66 18.95 23.27 35.11 17.99 9.34 7.05 10.06 10.70 15.9
P/S — 2.96 2.96 7.33 8.31 16.08 6.40 3.77 3.35 2.56 2.10 6.0
P/B — 6.62 6.62 6.37 6.70 13.82 5.24 2.36 1.88 1.39 1.15 5.7
EV/Sales — 2.29 2.29 6.09 7.04 14.91 5.20 2.27 1.84 1.06 0.76 4.8
EV/FCF — 7.59 7.59 15.48 18.43 30.66 13.12 6.33 5.51 4.68 3.47 12.2
Cash, $m
Cash, $m Operating cash flow — 15 37 62 79 175 182 177 133 85 84 +24.7%
Capex — 0 0 (1) 0 (1) (2) (1) (1) (1) (1) +22.7%
Free cash flow — 14 37 62 79 174 180 176 132 84 83 +24.7%
Balance, $m
Balance, $m Working capital — 24 48 181 255 418 547 781 645 628 571 +50.6%
Net debt — (25) (61) (193) (261) (416) (547) (742) (596) (555) (501) +47.3%
Shareholders’ equity — 19 45 180 255 416 555 787 704 683 629 +56.0%
Returns, %
Returns, % ROA — 14.64 37.13 40.84 29.19 42.61 28.77 26.25 21.99 12.09 10.85 (2.6) pt
ROIC — 0.00 0.00 0.00 0.00 0.00 1,709.17 267.20 65.52 41.74 33.78 +41.7 pt
ROE — 28.12 69.77 54.48 34.47 49.15 33.29 29.50 24.31 13.53 0.00 (14.6) pt
People
People Employees — — 209 251 311 362 480 581 599 660 — +17.9%
Revenue/emp, $m — 0.00 0.48 0.62 0.66 0.99 0.95 0.85 0.66 0.56 — n/m
Negative figures in brackets.
estimates

All 10 years →

Fiscal years to Dec 2025 · latest quarter Jun 2026

InMode Ltd. vs peers in Medical Devices (Q) = latest quarter vs a year earlier

Company Market cap P/E Fwd P/E Revenue growth (Q) EPS growth (Q) FCF growth (Q) Gross margin (Q) EBIT margin (Q) Compare
AHCO AdaptHealth Corp. $1.0B — (loss-making) — (loss-making) +10.90% (above 0%: growing) n/m −23.58% (below 0%: shrinking) 15.40% (20.91%) Compare
BVS Bioventus Inc. $899.9M 12.3× 17.2× +2.73% (above 0%: growing) +100.60% (above 0%: growing) −31.40% (below 0%: shrinking) 68.19% 6.81% Compare
QDEL QuidelOrtho Corporation $880.5M — (loss-making) — (loss-making) −11.57% (below 0%: shrinking) n/m +120.70% (above 0%: growing) 46.79% (1.21%) Compare
BBNX Beta Bionics, Inc. $842.1M — (loss-making) — (loss-making) +30.28% (above 0%: growing) n/m −45.46% (below 0%: shrinking) 57.26% (74.94%) Compare
KIDS OrthoPediatrics Corp. $841.3M — (loss-making) — (loss-making) +18.63% (above 0%: growing) n/m +146.64% (above 0%: growing) 74.28% (5.81%) Compare
VREX VAREX IMAGING $783.0M 34.8× 39.2× +3.69% (above 0%: growing) n/m +757.14% (above 0%: growing) 36.44% 10.83% Compare
INMD InMode Ltd. $771.1M 10.7× 11.8× −0.01% (below 0%: shrinking) −30.95% (below 0%: shrinking) −12.63% (below 0%: shrinking) 74.82% 12.82%
PACB Pacific Biosciences of California, Inc. $755.3M — (loss-making) — (loss-making) +5.52% (above 0%: growing) n/m −101.95% (below 0%: shrinking) 33.21% (91.22%) Compare
CTKB Cytek Biosciences, Inc. $701.9M — (loss-making) — (loss-making) +1.79% (above 0%: growing) n/m −30.25% (below 0%: shrinking) 58.63% (15.82%) Compare
Median of peers $841.7M — — +4.61% — −26.91% 52.03% (10.81%)

All 149 Medical Devices stocks →

InMode Ltd. (INMD) Latest News

19 Oct

Impact 4 · · Business Wire

13 Oct

Impact 3 · · PR Newswire

9 Sep

Impact 3 ·

16 Jul

Impact 3 ·

13 Jul

Impact 3 ·

10 Jul

Impact 4 ·

9 Jul

Impact 5 ·
Impact 4 · · InvestorsHub

30 Jun

Impact 4 ·

26 Jun

Impact 4 ·

24 Jun

Impact 4 · · Investor's Business Daily
Impact 4 · · Stocktwits
Impact 4 · · PR Newswire

27 May

Impact 3 · · Insider Monkey

6 May

Impact 4 · · The Motley Fool transcript
Impact 4 · · MarketBeat
Impact 3 · · Moby
Impact 3 · · PR Newswire

27 Apr

Impact 3 · · Simply Wall St.

14 Apr

Impact 3 · · MarketBeat

13 Apr

Impact 3 · · PR Newswire

18 Mar

Impact 4 · · MarketBeat
Impact 3 · · MarketBeat

15 Mar

Impact 4 · · Simply Wall St.

13 Mar

Impact 4 · · PR Newswire

23 Feb

Impact 4 · · PR Newswire

10 Feb

Impact 4 · · Moby transcript
Impact 4 · · GuruFocus.com transcript
Impact 4 · · MarketBeat transcript
Impact 4 · · The Motley Fool transcript
stockrow.com/INMD · Data as of Jun 30, 2026 · For information only; not investment advice. · © 2026 stockrow.com